IPS Biopharma AG

IPS Biopharma AG is the European subsidiary of Immunophotonics, Inc., a clinical-stage biotechnology company pioneering the field of Interventional Immuno-Oncology. The company focuses on transforming standard-of-care tumor ablation procedures into a systemic immunotherapy. Its proprietary technology, known as inCVAX, involves the intratumoral injection of an immune-activating drug immediately following a local tumor destruction technique like thermal ablation. The company's lead asset, IP-001, is a proprietary glycan polymer (galactated chitosan) designed to act as both an antigen depot and a potent immune stimulant. By sequestering tumor antigens liberated during ablation and recruiting antigen-presenting cells, IP-001 induces a systemic, tumor-specific T-cell response. This approach aims to eliminate not only the primary treated tumor but also distant micrometastases, addressing the high unmet need for preventing cancer recurrence and treating metastatic disease.